When Yu Yonggang was diagnosed with an aggressive form of lymphoma in 2013, he began a grueling three-year journey through 15 rounds of intravenous chemotherapy and 20 courses of oral chemo. With his cancer recurring and his body ravaged, doctors gave him about six months to live.
In Depth: The Battle to Make Cancer’s ‘Living Drug’ Affordable
2026年01月09日 17:55
A revolutionary CAR-T therapy offers a last hope for blood cancer patients, but its astronomical price tag has created a chasm in the market, where the treatment’s price is killing sales and forcing families into desperate choices
![]()
- Chimeric Antigen Receptor T-cell therapy, or CAR-T, retrains a patient’s own T-cells to recognize and attack cancer cells. For many patients with blood cancers like leukemia, it offers the hope of a one-time, curative treatment.
[财新双语通产品，是为有双语需求读者专门订制的优惠产品， 按此可享超值优惠订阅。]
版面编辑：喻竹杨洋
图片推荐
编辑推荐
最新文章
- 18:47股份行高层人事新动向 光大银行内部提拔高管
- 17:35欧盟接受大众安徽价格承诺方案 部分中国车企正在评估是否提交
- 16:32广西北海一头布氏鲸被渔船撞伤 当地称将视情进行保护救治
- 16:18中芯国际2025年四季度收入涨12.8% 2026年将持续扩产
- 16:03香港优化虚拟资产监管 比特币以太坊获纳入证券保证金融资抵押品
- 15:34亚当·图兹：实验猴价格暴涨——一个多重危机的侧影
- 15:27监管部门装上“眼睛” 工信部要求强化低空基础设施建设
- 13:45香港近期发生近40宗集体食物中毒 多与食用生蚝感染诺如病毒有关(含视频)
- 13:30AI颠覆传统互联网：大平台的危机，小企业的机会
- 11:55何飚调任广电总局副局长 此前任中国移动总经理不到两年
京公网安备 11010502034662号 
